<DOC>
	<DOCNO>NCT02045433</DOCNO>
	<brief_summary>The purpose study determine whether SABR boost therapy effective woman locally advanced cervical cancer without increase risk acute gastrointestinal ( GI ) genitourinary ( GU ) toxicity .</brief_summary>
	<brief_title>Stereotactic Body Radiation Therapy ( SABR ) Definitive Treatment Locally Advanced Cervical Cancer</brief_title>
	<detailed_description>Patients enrol study receive 45 Gray ( Gy ) 25 fraction intensity modulate external beam radiation therapy + weekly cisplatinum . Following completion Intensity Modulated Radiation Therapy ( IMRT ) , patient receive 28 Gy 4 fraction use stereotactic body radiation therapy technique .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<criteria>1 Locally Advanced stage Cervical Cancer 2 . Zubrod performance status 02 3 . Negative urine serum pregnancy test woman childbearing potential 4 . Agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study treatment 5 . Not candidate intracavitary brachytherapy 1 . Pregnancy 2 . Concurrent untreated cancer exclude nonMelanoma skin cancer 3 . Previous pelvic radiation 4 . Active Inflammatory Bowel disease , Collagen vascular disease systemic lupus erythematosus ( SLE ) , scleroderma 5 . Age &lt; 18 6 . Unable consent study 7 . Severely immunocompromised patient ( Transplant , immunosuppressive drug )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>